Study of Olverembatinib (HQP1351) in Patients With CP-CML
Status:
RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)